
New review: Why adapting mRNA vaccines for animals is harder than for people
Species differences, food safety requirements, and the cost of a single dose all factor in.
mRNA vaccines reshaped human medicine. Their use in animals remains limited in the field. A new review in Frontiers in Veterinary Science lays out what still has to be worked out. Most of it is practical rather than theoretical: how much of a dose reaches its target inside a cell, how differently each species responds, what happens to the ingredients in tissue that becomes food, and what a dose costs.1
The paper is a narrative review, not a trial. The authors searched 5 databases for work published between January 2015 and October 2026. They built the review around 4 case studies: African swine fever virus (ASFV), porcine reproductive and respiratory syndrome virus (PRRSV), animal coronaviruses, and pestiviruses.1
Most of the evidence comes from human medicine
The authors are blunt about the limits of what they had to work with. Much of what is known about how these vaccines work at the molecular level comes from studies of human mRNA vaccines: how the molecule is capped, how the delivery particles are built, and how the immune system reacts to polyethylene glycol (PEG), an ingredient in those particles. None of that says how the vaccines behave in a cow or a pig. Basic questions are still open for many livestock species, including how fast the delivery particles clear and how the adaptive immune response unfolds. Scaling a dose up from rodents is uncertain, because the dose-response relationship is not proportional and it differs from species to species.1
Delivery is still inefficient
Lipid nanoparticles ferry the mRNA into the cell, but only an estimated 1% to 2% of it reaches the cytosol, where the cell can read it. The other 98% to 99% is broken down in lysosomes. Repeated doses bring a second problem. Anti-PEG IgM and IgG antibodies turn up in roughly 20% to 40% of human serum samples. Comparable numbers for livestock and companion animals remain limited. Livestock get many vaccines over a production cycle, so repeated exposure could blunt later boosters.1
Food animals raise questions human vaccines never faced
The particles do not stay where the needle went. They have been found in the liver, spleen, gonads, and adrenal glands. In food-producing animals, that means withdrawal periods before slaughter have to account for them. Tissue distribution in one species cannot be assumed from human or rodent data. For most target veterinary species, that data is thin. The review describes the fate of RNA vaccine residue in the environment, in animal waste, and in slaughter waste as completely unknown.1
Swine research is furthest along
The strongest animal results come from pigs. Virulent genotype II strains of ASFV cause close to 100% mortality in domestic pigs. An mRNA construct encoding K205R, delivered in lipid nanoparticles, significantly delayed time to death after challenge. The authors call that partial protection, not complete.1
PRRSV costs the US pork industry $664 million a year and the worldwide swine industry more than $2.5 billion. In a 2025 preclinical study, an mRNA-lipid nanoparticle vaccine encoding fused GP5-M structural proteins produced a higher survival rate after lineage 8 challenge than a commercial inactivated vaccine. A multiepitope candidate aimed at the HP-PRRSV strain JX021 reached an 80% survival rate. Neither study tested protection against PRRSV strains of a different genetic makeup, including Type 1 European strains.1
Among animal coronaviruses, one result stands out. A self-cleaving mRNA-lipid nanoparticle vaccine carrying the spike, membrane, and nucleocapsid proteins of porcine deltacoronavirus was given to a sow. Her colostral IgA ran roughly 25 times higher than with a conventional inactivated vaccine. Her piglets got more passive transfer and better protection.1
Immunity duration and cost
Current mRNA formulations protect for 3 to 6 months. That is a problem for herd coverage. The review cites models for fast-spreading diseases, with PRRSV at a reproduction number of 2 or higher and foot-and-mouth disease virus between 3 and 55 in naive herds, which call for high and even coverage. In species with long production cycles, that would mean revaccinating more often than conventional vaccines require. Cost compounds it. The review puts the price per dose at more than 10 times conventional.1
Regulatory pathways are moving
Veterinary vaccines answer to a patchwork of agencies rather than one standard. In the United States, the USDA Center for Veterinary Biologics handles veterinary biologics on its own, separate from the FDA. The European Medicines Agency's Committee for Veterinary Medicinal Products put out a concept paper on the quality of veterinary mRNA vaccines in December 2024, then adopted a draft guideline for a 6-month public consultation in February 2026.1
One demand has no human counterpart. Eradication programs for foot-and-mouth disease, classical swine fever, and bovine viral diarrhea need DIVA compatibility. An mRNA vaccine that encodes a single antigen qualifies, as long as there is a companion test for an antigen it leaves out.1
Where the field stands commercially
The review points to several milestones. The first RNA-particle canine influenza vaccine, Merck Animal Health's Nobivac NXT Canine Flu H3N2, was approved in 2024. Zoetis won conditional USDA approval for a poultry avian influenza vaccine in February 2025. A fully synthetic mRNA foot-and-mouth disease vaccine developed in New South Wales, Australia, was unveiled in August 2025. It is still under evaluation for emergency-use registration by the Australian Pesticides and Veterinary Medicines Authority, with no approval for routine field use.1
Storage has improved too. Freeze-dried self-amplifying RNA formulations made with 10% sucrose by weight per volume have held up for at least 1 week at 25 °C and at least 1 year at 2 °C to 8 °C.1
The companion animal rabies vaccines
What comes next
The authors point to self-amplifying RNA, formulations that survive warmer storage, artificial intelligence for antigen design, and better delivery systems. They also flag the limits of their own work. The search covered 5 databases and English-language publications only, with no formal quality assessment tool and no quantitative meta-analysis. They ask readers to treat the conclusions as a critical synthesis of the available evidence rather than a quantitative assessment. The work was funded by the Deanship of Graduate Studies and Scientific Research at Qassim University, with no commercial or financial conflicts declared.1
References
- Ashfaq MS, Tharwat M, Shaukat A, et al. mRNA vaccines for zoonotic and veterinary diseases: translational barriers, delivery innovations, and strategic integration within the One Health framework. Front Vet Sci. 2026;13:1971000. doi:10.3389/fvets.2026.1971000
- Stachura K, Davis R, Carritt K, Mogler M, Xu Z, Tarpey I. A novel, safe, non-adjuvanted alphavirus RNA particle vaccine expressing the rabies virus glycoprotein induces a three-year duration of immunity in dogs and cats after a single vaccine dose. Vaccines (Basel). 2025;13(12):1176. doi:10.3390/vaccines13121176
Related to this article









